Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. (NYSE American: YCBD) generates a steady flow of corporate, financial, and strategic news tied to its position in the hemp-derived wellness and cannabinoid products space. Company press releases and SEC filings highlight developments across its cbdMD and Paw CBD brands, ATRx Labs functional mushroom products, and Herbal Oasis hemp-derived THC social seltzers, as well as capital markets activity and exchange-listing matters.
News for YCBD often covers operating performance, including updates on net sales, gross profit, and operating loss trends disclosed in conjunction with annual and quarterly results. The company has reported multiple years of operating improvement and has discussed cost management, product portfolio optimization, and marketing investments in its communications. Investors following YCBD news also see disclosures about preferred stock financings, such as Series B and Series C Convertible Preferred Stock, and the establishment of an equity line of credit registered on Form S-1.
Regulatory and listing-related announcements form another key part of cbdMD’s news flow. The company has reported regaining full compliance with NYSE American continued listing standards after addressing equity-related deficiencies, and it has furnished related information through Form 8-K filings. Policy commentary around federal discussions on cannabinoids and hemp-derived products, and how those discussions may affect research and investment in the category, also appears in its releases.
Strategic updates, including the asset acquisition of Gaia Botanicals, LLC and its Bluebird Botanicals brand and online CBD marketplace, are disclosed through press releases and 8-K filings. These items provide detail on how cbdMD is expanding its brand portfolio, intellectual property base, and product offerings in CBD and related categories. For investors and observers, the YCBD news page offers a centralized view of earnings communications, capital transactions, regulatory milestones, and brand-level initiatives across cbdMD’s wellness platform.
cbdMD (NYSE American: YCBD) reported a sequential revenue increase and improved liquidity for Q1 FY2026 ended December 31, 2025. Net sales were $5.0 million, up 12% sequentially; working capital rose to $5.4 million and cash to $3.4 million. The company closed a $2.25 million Series C and completed the acquisition of Bluebird Botanicals, including GRAS status for full‑spectrum CBD, with integration underway.
Operating loss was $286,000 and adjusted EBITDA was a $36,000 loss; net loss attributable to common shareholders was $0.32 million (loss of $0.04 per share).
cbdMD (NYSE American: YCBD) will host a conference call to discuss its December 31, 2025 first quarter financial results and business progress.
The call is set for 4:20 p.m. ET on Tuesday, February 17, 2026. Dial-in for USA/Canada is 888-880-3330. A webcast and replay are available through February 17, 2027.
cbdMD (NYSE American: YCBD) expanded distribution for its Herbal Oasis THC-infused social seltzer into Louisiana via an expanded partnership with Morales Beverage Group (MBG). Management expects initial shipments to begin in late February 2026, leveraging MBG’s statewide infrastructure after strong early performance in Texas. The release cites U.S. THC beverage sales of $1.6 billion in 2025 and a projected $3.5 billion by 2030 (Fact MR), and highlights Oasis’s blend of hemp-derived THC, CBD, CBG and adaptogenic mushrooms plus flavor SKUs like Lemon Lift and Mango Bliss.
cbdMD (NYSE American: YCBD) announced an integrated regulatory science and safety program following its January 2026 acquisition of substantially all assets of Bluebird Botanicals. The move combines Bluebird's full-spectrum GRAS dossier with cbdMD's clinical and toxicology data to pursue new GRAS work and stronger regulatory engagement.
Management cites an estimated 10% step in revenue growth from the acquisition and says the program will be executed primarily through internal scientific, quality, and regulatory teams to reduce external consulting costs.
cbdMD (NYSE American: YCBD) announced the closing of its acquisition of substantially all assets of Bluebird Botanicals on January 14, 2026. The transaction was an asset purchase completed using an initial share issuance plus earnout shares, and the company referenced a Form 8-K filed with the SEC on January 13, 2026 for terms. cbdMD said the deal adds an established revenue base, branded consumer loyalty, and a portfolio of patented-process technologies and regulatory compliance documentation. Management expects cost and revenue synergies from consolidated supply chain, manufacturing, and shared services, and said the acquisition supports its goal of achieving positive EBITDA and net income as it broadens product offerings and cross-brand distribution.
cbdMD (NYSE American: YCBD) reported fiscal 2025 results for the year ended September 30, 2025, citing its third consecutive year of operating improvement and steps to strengthen the balance sheet and regain exchange compliance.
Key facts: Net sales $19.19M, gross margin 62%, loss from operations $2.16M (improved vs $3.32M in 2024), net loss to common $4.38M, cash $2.26M, and shareholders' equity ≈ $7.23M. Financing actions include $1.7M Series B (closed Sept 2025), $2.25M Series C (closed Dec 18, 2025), and a $20M equity line of credit (Dec 15, 2025 amendment).
The company said it resolved NYSE American listing deficiencies and noted an audit explanatory paragraph regarding its ability to continue as a going concern.
cbdMD (NYSE American: YCBD) reported fiscal 2025 results for the year ended September 30, 2025, citing its third consecutive year of operating improvement and steps to strengthen the balance sheet and regain exchange compliance.
Key facts: Net sales $19.19M, gross margin 62%, loss from operations $2.16M (improved vs $3.32M in 2024), net loss to common $4.38M, cash $2.26M, and shareholders' equity ≈ $7.23M. Financing actions include $1.7M Series B (closed Sept 2025), $2.25M Series C (closed Dec 18, 2025), and a $20M equity line of credit (Dec 15, 2025 amendment).
The company said it resolved NYSE American listing deficiencies and noted an audit explanatory paragraph regarding its ability to continue as a going concern.
cbdMD (NYSE American: YCBD) announced on December 19, 2025 the closing of a private placement of 1,000,000 shares of Series C convertible preferred stock for gross proceeds of $2.25 million.
The company expects net proceeds of approximately $2.1 million to be used for working capital, general corporate purposes, and to support strategic initiatives, including expanding distribution of its consumer brands.
The Series C carries a 10% annual dividend and is convertible at the holder's option into common stock at an initial conversion price of $2.25 per share, with anti-dilution protection and rights substantially the same as the company’s Series B preferred.
cbdMD (NYSE American: YCBD) announced on December 19, 2025 the closing of a private placement of 1,000,000 shares of Series C convertible preferred stock for gross proceeds of $2.25 million.
The company expects net proceeds of approximately $2.1 million to be used for working capital, general corporate purposes, and to support strategic initiatives, including expanding distribution of its consumer brands.
The Series C carries a 10% annual dividend and is convertible at the holder's option into common stock at an initial conversion price of $2.25 per share, with anti-dilution protection and rights substantially the same as the company’s Series B preferred.
cbdMD (NYSE American: YCBD) will host a conference call on Friday, December 19, 2025 at 4:20 p.m. ET to discuss its September 30, 2025 fourth quarter and fiscal year 2025 financial results and business progress.
Investors in the USA/Canada can join by phone at 888-880-3330. A live webcast and replay are available via the provided link and will remain accessible through December 19, 2026.